drugset / Trial / NCT02283801

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.

NCT02283801

Phase 1 Completed 32 enrolled Bial - Portela C S.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

Single centre, open-label, multiple doses, one-sequence design study in two parallel groups of healthy volunteers

Timeline

Start
2006-11
Primary completion
2007-01
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 1200 mg
Subject Lamotrigine Small molecule 150 mg

Indications